Most who did are dead.

“Pancreatitis is also a well-described complication of Videx and Zerit.”

– FDA Talk Paper, Jan 5, 2001

ddI (Videx)
Peripheral neropathy    16-34%
Pancreatitis    7-13%
Diarrhea    16-34%
Abacavir (Ziagen)
Nausea    47%
Diarrhea    12%
Decreased appetite    11%
Insomnia    7%
Hypersensitivity reaction    3-5%
Side Effects Reported    Incidence Rates*
NUCLEOTIDE ANALOG
Adefovir (Preveon)
Renal (kidney) toxicities    17-32%
NNRTIs (NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS)
Nevirapine (Viramune)
Rash    24-37%
Delavirdine (Rescriptor)
Rash    18%
Neutropenia    3-7%
Elevated amylase levels    1-7%
Efavirenz (Sustiva)
Central nervous system problems (headache, insomnia, dizziness, malaise,
anxiety    25-40%
Rash    12%
Nausea    10-20%

At the Owen Clinic of the University of California, San Diego, a study of
nearly 5,000 patients who sought care for HIV showed a drop in the death
rate starting in 1995, but then an upswing among those who came to the
clinic after 1998. (5 )
A survey of almost 3,000 people enrolled in five US antiretroviral trials
between December 1996 and December 2001 plotted a dogged doubling of the
death rate every 12 months, from 3.9 percent after one year of follow-up,
to 7.9 percent after two, and to 13.1 percent after three. (6)
(5). Mathews W, Barber E. Rising mortality rates among recent entrants to
care for HIV infection. 10th Conference on Retroviruses and Opportunistic
Infections. February 10-14, 2003. Boston. Abstract 911.
(6). Reisler RB, Han C, Burman WJ, et al. Grade 4 events are as important
as AIDS events in the era of HAART. JAIDS 2003;34:379-386.